This site is intended for health professionals only

Strong growth forecast for Novartis

Close Up/Macro Study of Various British Sterling Paper and Polymer Bank Notes

teaser

Analysts are predicting second-quarter net income growth for Novartis of 14%, to $1.88bn, on strong sales of Diovan

RELATED ARTICLES
Denosumab for menopausal and cancer-related bone loss
Patient knowledge of colorectal cancer therapy side-effects
Understanding compassionate-use programmes
ECCMID: Developments in invasive fungal disease
ECCO President’s preview of the Congress





Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Subscribe
FOLLOW US

IMPORTANT LINKS

MORE FROM COGORA

© Cogora 2026
Cogora Limited. 1 Giltspur Street, London EC1A 9DD Registered in the United Kingdom. Reg. No. 2147432

Cogora
x